Chronic myeloid leukemia (CML) arises when the BCR–ABL1 fusion oncogene forms and is activated in hematopoietic stem cells (HSCs) [1,2]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.